SuperworthDecoy Therapeutics DCOY
- Market cap
- $635.5K
- PE
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | $0 | n/a | n/a | n/a | $227.6K | |
| Cost of revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Gross profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| R&D | $1M−73% | $60K−99% | $243K−94% | $214.4K−91% | $137.2K−87% | $175.3K+193% | $75.5K−69% | $116.4K−46% | $61.8K−55% | $114.4K−35% | $749.8K+893% | $1.3M+1021% |
| SG&A | $1.5M−18% | $910.7K−49% | $1.5M−10% | $1.3M−23% | $869.2K−42% | $1.3M+44% | $1.6M+8% | $849.2K−32% | $833.3K−4% | $402.2K−69% | $1.5M−7% | $1.3M+56% |
| −$2.5M−83% | −$970.7K−85% | −$1.8M−67% | −$1.5M−63% | −$1M−60% | −$1.5M+53% | −$1.7M−3% | −$965.6K−34% | −$895.1K−11% | −$9M+507% | −$2.3M+33% | −$2.6M+173% | |
| Pre-tax income | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Net income | −$2.4M−83% | −$881.8K−86% | −$1.7M−68% | −$1.4M−63% | −$972.1K−60% | −$1.5M+66% | −$1.7M−0% | −$957.8K−33% | −$873.5K−10% | −$9M+513% | −$2.2M+30% | −$2.4M+148% |
| −$937.80−90% | −$322.20−92% | −$588.60−82% | −$426.60−79% | −$136.56−85% | −$183.60−43% | −$240.07−59% | −$81.21−81% | −$21.72−84% | n/a | −$4.18−98% | −$4.46−95% | |
| 2.6K+67% | 2.7K+75% | 2.9K+75% | 3.3K+77% | 7.1K+173% | 8K+193% | 7.1K+145% | 11.8K+254% | 40.1K+464% | n/a | 532K+7370% | 532K+4411% |
Gross profit: 17 periods, Q2 FY15 to Q2 FY19: not printed by the filing, worked out from its own lines.
EPS, diluted: 6 periods, Q4 FY19 to Q4 FY24: quarter's net income to common over its shares, to the cent.
Diluted shares: 6 periods, Q4 FY19 to Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Decoy Therapeutics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| DCOYDecoy Therapeutics | $635.5K | n/m | n/a | n/m | n/m | n/m | |
| SBFMSunshine Biopharma | $581.6K | n/m | n/a | 0.0× | −3% | −16.5% | |
| JAGXJaguar Health | $702.9K | n/m | n/a | 0.0× | +136% | n/m | |
| LABTLakewood-Amedex Biotherapeutics | $734.6K | n/m | n/a | n/m | n/m | n/m | |
| NXTSNexentis Technologies | $761.8K | n/m | n/a | n/m | n/m | n/m | |
| VBIOValion Bio | $834.3K | n/m | n/a | n/m | n/m | n/m | |
| ARTLArtelo Biosciences | $1.3M | n/m | n/a | n/m | n/m | n/m | |
| LNAILunai Bioworks | $1.5M | n/m | n/a | n/m | n/m | n/m | |
| GNPXGenprex | $1.5M | n/m | n/a | n/m | n/m | n/m | |
| GOVXGeoVax Labs | $1.5M | n/m | n/a | n/a | −100% | n/a | |
| ONCOOnconetix | $1.7M | n/m | n/a | n/m | n/m | n/m | |
| Peer median | $1.1M | n/a | n/a | 0.0× | −3% | −16.5% |
More on Decoy Therapeutics
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .